Schizophrenia

Paul Crawford; Kendrick V. Go

PAUL CRAWFORD, MD, AND KENDRICK V. GO, MD

This is a corrected version of the article that appeared in print.

Am Fam Physician. 2022;106(4):388-396

Related Letter to the Editor: Long-Acting Injectable Clozapine Not Available in the United States

Patient information: See related handout on schizophrenia.

Author disclosure: No relevant financial relationships.

Schizophrenia is the most common psychotic mental disorder, and those affected have two to four times higher mortality than the general population. Genetic and environmental factors increase the risk of developing schizophrenia, and substance use disorder (particularly cannabis) may have the strongest link. Schizophrenia typically develops in young adulthood and is characterized by the presence of positive and negative symptoms. Positive symptoms include hallucinations, delusions, and disorganized speech. Negative symptoms include blunted affect, alogia, avolition, asociality, and anhedonia. Symptoms must be present for at least six months and be severe for at least one month to make a diagnosis. Because schizophrenia is debilitating, it should be treated with antipsychotics, and early treatment decreases long-term disability. Treatment should be individualized, and monitoring for effectiveness and adverse effects is important. Patients with a first episode of psychosis who receive a formal diagnosis of schizophrenia should be treated in a coordinated specialty care program. Second-generation antipsychotics are the preferred first-line treatment because they cause fewer extrapyramidal symptoms. Patients with schizophrenia who are treated with second-generation antipsychotics are at increased risk of cardiovascular disease and should receive at least annual metabolic screening and counseling with interventions to prevent weight gain and encourage smoking cessation. Treatment-resistant schizophrenia should be treated with clozapine. Adjunctive treatments include electroconvulsive therapy, antidepressants, and cognitive behavior therapy for psychosis. Family and social support are keys to improved outcomes.

Schizophrenia is the most common psychotic mental disorder in the United States. It affects approximately 1% of the population and accounts for up to $23 billion in U.S. health care expenditures.¹ Black people have disproportionately higher rates of being diagnosed with schizophrenia compared with non-Latino White people, which may be because of physician bias, less access to health care, and underdiagnosis of other psychiatric conditions, such as bipolar depression.^2–4 According to the Diagnostic and Statistical Manual of Mental Disorders, 5th ed., men tend to have a syndromic phase between 18 and 25 years of age.⁵ In women, there are two peaks of syndromic presentation, the first between 25 years of age and mid-30s, and the second after 40 years of age.⁵ Initial presentation before 15 years of age is possible but rare.⁵ Medication adherence is associated with decreased risk of relapse into active-phase schizophrenia.⁶ Primary care physicians should be aware that patients with schizophrenia have an increased risk of cardiovascular disease as well as overall mortality.⁷

Clinical recommendation	Evidence rating	Comments
Patients with schizophrenia should be treated with first- or second-generation antipsychotics and continue maintenance therapy while being monitored for effectiveness and adverse effects.^{20,24,31,52,53}	A	Practice guideline, Agency for Healthcare Research and Quality systematic review, Cochrane review, and cohort studies that showed improvement in symptoms and mortality
Schizophrenia resistant to first- or second-generation anti-psychotics should be treated with clozapine (Clozaril).^20,44	B	Practice guideline and systematic review of randomized controlled trials that showed improved symptom control and mortality
Adjunctive treatments with psychosocial therapies such as cognitive behavior therapy for psychosis, psychoeducation, supported employment services, assertive community care, and family interventions should be offered.²⁴	B	Agency for Healthcare Research and Quality systematic review of multiple cohort and randomized controlled trials that showed improved social function
Patients with a first episode of psychosis who receive a formal diagnosis of schizophrenia should be treated in a coordinated specialty care program.^20,24	B	Practice guideline and Agency for Healthcare Research and Quality systematic review that showed decreased recurrences of psychosis and improved social outcomes

Recommendation	Sponsoring organization
Do not prescribe antipsychotic medications to patients for any indication without appropriate initial evaluation and ongoing monitoring.	American Psychiatric Association
Do not routinely prescribe two or more antipsychotic medications concurrently.	American Psychiatric Association

Pathophysiology

The pathways associated with the development of psychotic symptoms involve altered neurotransmission of glutamate, serotonin, and dopamine in the hippocampus, midbrain, corpus striatum, and prefrontal cortex.⁸ Although the pathogenesis is unclear, proinflammatory cytokines may play a role in the development of schizophrenia and have recently prompted an interest in the therapeutic use of anti-inflammatory and immunomodulatory agents.⁹ Disrupted neural function during adolescent development and subcortical dopamine dysregulation are the neuromolecular processes that may account for symptoms ranging from cognitive deficits to psychosis.¹⁰

Etiology

The development of schizophrenia is best understood as a multifactorial process involving the interaction of genetic predisposition and environmental factors, also known as the polygenic threshold model.¹¹ Epidemiologic studies suggest a hereditary pathogenesis for psychotic disorders, with higher rates in siblings and parents with a psychotic disorder and a 50% concordance of genetic loci between identical twins.⁸

Environmental factors that increase the risk of schizophrenia during fetal development and early life include infections (e.g., rubella, influenza, Toxoplasma gondii, herpes simplex virus type 2), and nutritional deficiencies (e.g., folic acid, iron, vitamin D).¹² Pregnancy and birth complications, specifically neonatal hypoxic events, appear to be significant risk factors for the development of schizophrenia.¹³ Other observed risk factors include cannabis use, childhood trauma, and socioeconomic status.¹² These risk factors work at the epigenetic level to show genetic and inflammatory predispositions.

A large longitudinal prospective study of adolescents in New Zealand showed a relationship between cannabis use and the development of schizophrenia.¹⁴ A meta-analysis that studied the association between the degree of cannabis consumption and psychosis revealed an odds ratio of 3.90 (95% CI, 2.84 to 5.34) for the risk of schizophrenia in the heaviest cannabis users compared with nonusers, with a dose-response relationship between all levels of use and the risk for psychosis.¹⁵ It is hypothesized that the release of dopamine resulting from excess stimulation of cannabinoid receptor 1 can at least partially trigger schizophrenia in genetically predisposed individuals.¹² Other studies have suggested a strong association between substance use disorder and risk of developing or exacerbating symptoms of schizophrenia.^16,17 When primary care physicians are screening for substance use disorders in adolescents, they should discuss the association of cannabis use with schizophrenia, especially when a family history or other identifiable risk factors are present.

Clinical Presentation

It is important to identify schizophrenia early in the course of disease because those who are treated early have better long-term outcomes.¹² There are no biomarkers or neuroimaging tests that aid in the diagnosis of schizophrenia.^8,12 Therefore, primary care physicians must be vigilant in identifying those with psychotic symptoms, using current diagnostic criteria as well as specialty care referral to aid in diagnosis.

Schizophrenia is characterized by two sets of categorical symptoms, with at least one positive symptom and either one negative symptom or grossly disorganized or catatonic behavior present for at least six months. Positive symptoms include bizarre or confused behavior with hallucinations, delusions, and disorganized speech.⁵ Negative symptoms comprise a lack of normal function and include blunted affect, alogia (i.e., reduction in quantity of words spoken), avolition (i.e., reduced goal-directed activity due to decreased motivation), asociality, and anhedonia.⁵ Symptoms must be present for at least six months and be severe for at least one month (or less if receiving clinical treatment), and must be significantly debilitating to a person's level of functioning, although milder symptoms are usually present throughout the six-month period.⁵ Other psychiatric disorders and medical conditions that should be ruled out when patients present with symptoms are reviewed in Table 1^18,19 and Table 2.¹⁸ Primary care physicians can use Figure 1 to assist with the diagnosis of schizophrenia.

Psychiatric condition	Distinguishing features
Bipolar disorder with psychotic features	Psychotic symptoms during manic or depressive episodes
Brief psychotic disorder	Delusions, hallucinations, and other psychotic symptoms lasting more than one day but less than one month
Delusional disorder	Fixation on false beliefs or nonbizarre delusions without other psychotic symptoms
Major depressive disorder with psychotic features	Psychotic symptoms with mood disturbances qualifying for concomitant major depressive disorder diagnosis
Obsessive-compulsive disorder	Significant obsessions, compulsions, and preoccupations
Posttraumatic stress disorder	Symptoms related to reliving inciting traumatic event
Schizoaffective disorder	Mania or depression occurring concomitantly with psychotic symptoms; psychotic symptoms without mood disturbance
Schizophreniform disorder	Psychotic symptoms lasting at least one month, but less than six months
Schizotypal personality disorder	No hallucinations or delusions with personality features

Medical condition	Distinguishing features	Laboratory findings
Cushing syndrome	Abdominal striae, easily bruised, fat pads around shoulders, hirsutism, round face	Elevated 24-hour urine cortisol level
Delirium	Confused thinking and reduced awareness of surrounding environment	—
Dementia	Cognitive and memory deficits	—
Intracranial tumor	Focal neurologic deficits	Computed tomography or magnetic resonance imaging of the brain detecting a lesion
Paraneoplastic and nonparaneoplastic autoimmune syndromes with psychosis	Memory problems, seizures	N-methyl-d-aspartate receptor antibodies, anti-metabotropic glutamate antibodies, presence of ovarian teratoma on ultrasonography, abnormal electroencephalography, anti-Hu antibodies
Porphyria	Proximal muscle weakness, severe abdominal pain, tachycardia	Hyponatremia, elevated urine porphobilinogen
Substance abuse	Abnormal vital signs, needle marks, poor nutrition	Positive results on urine drug screen, elevated blood alcohol level
Systemic lupus erythematosus	Alopecia, discoid rash, fever, malar rash, oral ulcers, pleural or pericardial friction rub	Anemia, elevated antinuclear antibodies titer, pleural effusion on chest radiography, proteinuria, low complements; presence of anti-Smith antibodies, antiphospholipid antibodies, lupus anticoagulant, anti-double stranded DNA, anticardiolipin or anti-beta₂-glycoprotein antibodies
Thyroid disorders	Coarse hair, dry skin, exophthalmos, tachycardia or bradycardia	Abnormal thyroid-stimulating hormone level
Vitamin B₁₂ deficiency	Ataxia, atrophic glossitis, memory impairment, muscle weakness	Low serum vitamin B₁₂, macrocytic anemia, and indirect bilirubin levels
Wilson disease	Ataxia, dysarthria, hepatomegaly, hyper-reflexia, jaundice, Kayser-Fleischer rings in the cornea	Basal ganglia lesions on magnetic resonance imaging, Coombs-negative hemolytic anemia, elevated liver enzymes

The natural course of schizophrenia can be divided into four stages: premorbid, prodromal, syndrome, and chronic/residual. During the premorbid and prodromal stages, which typically encompass ages between birth and early 20s, people with schizophrenia may have no symptoms. Although early detection and intervention are ideal for improved outcomes, a lack of sensitive and specific diagnostic criteria for premorbid and prodromal schizophrenia is a known barrier that can hinder the implementation of proven therapeutic strategies.²⁰

Once in the syndromic phase, patients will meet the criteria for the diagnosis of schizophrenia. The severity of the disease during the chronic/residual stage will be impacted by social and medical factors such as a social support system and adherence to maintenance therapy to avoid relapses.¹²

Treatment

The primary goal for initial treatment of schizophrenia should be to reduce acute positive symptoms by using first-or second-generation antipsychotics (Table 3^20–29), allowing the patient to return to a baseline level of function and prevent long-term disability. Treatment for schizophrenia should continue for life.³⁰

Medication	Initial dosage (mg per day)	Typical dosage range (mg per day)	Common adverse effects	Serious adverse effects	Comments	Cost*
First-generation antipsychotics
Chlorpromazine	25 to 100	200 to 800	Dry mouth, elevated prolactin levels, extrapyramidal symptoms, glucose intolerance, postural hypotension, somnolence, weight gain	Neuroleptic malignant syndrome, tardive dyskinesia	Has the most anticholinergic effects of the first-generation antipsychotics	$25 for 30 25-mg tablets
Fluphenazine	2.5 to 10	6 to 20	Akathisia, parkinsonism, dystonia, hyperprolactinemia	Neuroleptic malignant syndrome, tardive dyskinesia	—	$20 for 30 2.5-mg tablets
Haloperidol	1 to 15	5 to 20	Dry mouth, extrapyramidal symptoms, galactorrhea, hyperprolactinemia, hypotension, somnolence, tachycardia	Neuroleptic malignant syndrome, tardive dyskinesia, prolonged QT syndrome	—	$6 for 30 1-mg tablets
Loxapine	20	60 to 100	Dry mouth, extrapyramidal symptoms, galactorrhea, hyperprolactinemia, hypotension, somnolence, tachycardia	Neuroleptic malignant syndrome, tardive dyskinesia	—	$20 for 60 10-mg capsules
Perphenazine	8 to 16	8 to 32	Dry mouth, extrapyramidal symptoms, galactorrhea, hyperprolactinemia, hypotension, somnolence, tachycardia	Neuroleptic malignant syndrome, tardive dyskinesia	—	$16 for 30 8-mg tablets
Second-generation antipsychotics
Aripiprazole (Abilify)	10 to 15	10 to 15	Anxiety, constipation, dizziness, headache, insomnia	Agranulocytosis, neuroleptic malignant syndrome, tardive dyskinesia	May reduce hyperprolactinemia when used with other antipsychotics; does not impact lipids as much as other second-generation antipsychotics²¹	$10 ($580) for 30 10-mg tablets
Brexpiprazole (Rexulti)	1	2 to 4	Hyperlipidemia, weight gain, akathisia, somnolence	QT prolongation	—	$— ($1,300) for 30 1-mg tablets
Cariprazine (Vraylar)	1.5	1.5 to 6	Hyperprolactinemia, weight gain, somnolence	QT prolongation	—	$— ($1,300) for 30 1.5-mg capsules
Clozapine (Clozaril)	12.5 to 25	300 to 450	Hyperlipidemia, diabetes mellitus, orthostasis, seizures	Agranulocytosis (complete blood count should be obtained weekly for six months, then every two weeks for six months, then monthly), seizures, tardive dyskinesia, myocarditis	Primarily for treatment of severe refractory schizophrenia	$7 ($65) for 10 25-mg tablets
Lurasidone (Latuda)	40	40 to 160	Hyperlipidemia, diabetes, parkinsonism, somnolence, nausea	Neuroleptic malignant syndrome, tardive dyskinesia, QT prolongation	—	$— ($1,400) for 30 40-mg tablets
Olanzapine (Zyprexa)	5 to 10	10 to 20	Weight gain, hyperlipidemia, diabetes, akathisia, hyperprolactinemia, postural hypotension	Neuroleptic malignant syndrome, tardive dyskinesia	Do not use with benzodiazepines Patients who smoke may need a dose increase of 30% because of increased metabolism Increased incidence of weight gain compared with other second-generation antipsychotics²⁰	$5 ($460) for 30 5-mg tablets
Paliperidone ER (Invega)	6	3 to 12	Hyperprolactinemia, hyperlipidemia, weight gain, priapism	Neuroleptic malignant syndrome, tardive dyskinesia	Is the active metabolite of risperidone	$90 ($370) for 30 6-mg tablets
Quetiapine (Seroquel)	Immediate release: 50 Extended release: 300	400 to 800	Hyperlipidemia, agitation, dizziness, dry mouth, hypotension, somnolence, weight gain	Agranulocytosis, neuroleptic malignant syndrome, tardive dyskinesia	Elevated discontinuation rate compared with other second-generation antipsychotics²²	$4 ($200) for 30 50-mg tablets $7 ($500) for 30 300-mg tablets
Risperidone (Risperdal)	2	2 to 8	Anxiety, hyperprolactinemia, hypotension, insomnia, metabolic changes, nausea, weight gain	Agranulocytosis, neuroleptic malignant syndrome, tardive dyskinesia	Higher incidence of increased prolactin levels and extrapyramidal effects than other second-generation antipsychotics	$3 ($250) for 30 2-mg tablets
Ziprasidone (Geodon)	40	80 to 160	Agitation, hypotension, metabolic changes, nausea, somnolence, tachycardia, weight gain	Agranulocytosis, neuroleptic malignant syndrome, tardive dyskinesia	Least amount of weight gain compared with other atypical antipsychotics	$8 ($600) for 30 40-mg capsules

A GENERAL APPROACH TO THE PATIENT

Patients with schizophrenia should continue maintenance therapy while being monitored for treatment effectiveness and adverse effects.^20,24,31 The goal of maintenance therapy is to prevent reoccurrence of symptoms and maximize social function and quality of life.

There is no reliable strategy or data to predict how a patient with schizophrenia will respond to medication or the patient's risk of adverse effects. Factors that impact selection of medication include individual preference, prior treatment response, adherence history, relevant medical history and risk factors, adverse effects, and long-term treatment planning, including cost and access to medication.²³

Primary care physicians should begin by prescribing an antipsychotic with a favorable adverse effect profile that is cost-effective, while establishing long-term treatment or referring the patient to a specialist. The U.K.-based National Institute for Health and Care Excellence recommends that primary care physicians consult a psychiatrist and immediately refer the patient to mental health services when prescribing antipsychotic medications for psychotic symptoms.³² Primary care physicians who are comfortable prescribing antipsychotics can play a vital role in treating patients in resource-constrained environments. A therapeutic relationship that promotes medication adherence while coordinating with social services that help address social determinants of health (e.g., living situation, employment, drug use) can reduce psychiatric hospitalizations.³³

FIRST- AND SECOND-GENERATION ANTIPSYCHOTICS

First-generation antipsychotics are dopamine receptor antagonists. Second-generation antipsychotics are serotonin receptor antagonists, which have less impact on dopamine metabolism. There is no evidence-based algorithm or ranking guidance in selecting a first- or second-generation antipsychotic because of the heterogeneity of clinical trials and limited number of head-to-head comparisons.²⁰ Second-generation antipsychotics are generally preferred as first-line agents for acute treatment and maintenance therapy because of their reduced risk of extrapyramidal symptoms compared with first-generation antipsychotics.³⁴ However, second-generation antipsychotics still carry a significant risk of extrapyramidal symptoms.

Both generations of antipsychotics can produce extrapyramidal symptoms of pseudoparkinsonism, akathisia (i.e., a sensation of inner restlessness and inability to be still), and dystonia. First-generation antipsychotics, which are comprised of typical antipsychotics phenothiazines (e.g., chlorpromazine), thioxanthenes (e.g., thiothixene), and butyrophenones (e.g., haloperidol), are more likely than second-generation antipsychotics to contribute to developing these conditions. Antihistamines, nonselective beta blockers, or benzodiazepines are used to treat symptoms.²⁰

Tardive dyskinesia, characterized by repetitive, jerking movements that occur in the face, neck, and tongue, is another adverse effect of first- and second-generation antipsychotics. It is more common in older female patients with diabetes mellitus.³⁵ Moderate to severe tardive dyskinesia should be treated with reversible vesicular monoamine transporter 2 inhibitors, deutetrabenazine (Austedo) and valbenazine (Ingrezza; only available through specialty pharmacies).³⁶ The most common adverse effect is somnolence. Patients should be monitored for QT-prolongation. Vitamin E, vitamin B₆, and amantadine may reduce symptoms of tardive dyskinesia.³⁷

Second-generation antipsychotics, also known as atypical antipsychotics, are associated with the development of metabolic syndrome, which includes weight gain, hyperglycemia with the potential of developing insulin resistance, and lipid abnormalities.^38,39 A meta-analysis found a significant reduction in body mass index and insulin resistance, but not fasting blood glucose levels, in patients taking a second-generation antipsychotic with metformin compared with taking the antipsychotic with placebo.⁴⁰ Another meta-analysis determined that metformin compared with placebo achieved clinically relevant weight loss of 7% of body weight (number needed to treat [NNT] = 3).⁴¹ A new combination formulation of olanzapine/samidorphan (Lybalvi) has been approved by the U.S. Food and Drug Administration (FDA) and was associated with significantly less weight gain and smaller increases in waist circumference than olanzapine (Zyprexa) alone.⁴² There are no head-to-head studies that compare the efficacy of samidorphan (an opioid receptor antagonist) with metformin to justify the cost associated with the new combination medication.

TREATMENT-RESISTANT SCHIZOPHRENIA

Treatment-resistant schizophrenia is the persistence of significant symptoms despite adequate pharmacologic treatment.²⁶ To determine severity of symptoms and response to treatment, physicians can use validated scoring scales (Table 4).^26,43 Higher scores are indicative of treatment-resistant schizophrenia and should encourage a goal-oriented discussion of escalation of therapy and evaluation of psychosocial interventions. The scales should not be used for diagnostic purposes.

Brief Psychiatric Rating Scale (BPRS)

https://www.smchealth.org/sites/main/files/file-attachments/bprsform.pdf?1497977629

Clinical Global Impression Schizophrenia (CGI-SCH)

https://medworksmedia.com/product/clinical-global-impressions-cgi/

Negative Symptom Assessment-16 (NSA-16)

https://eprovide.mapi-trust.org/instruments/negative-symptom-assessment

Positive and Negative Syndrome Scale 6- or 30-item version (PANSS-6 or PANSS-30)

https://nationalepinet.org/wp-content/uploads/2020/08/PANSS-6_8-3-20.pdf

https://www.sandiego.edu/teamup/documents/DRL-PANSS.pdf

Scale for the Assessment of Negative Symptoms (SANS)

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id=phd000807.2

Scale for the Assessment of Positive Symptoms (SAPS)

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id=phd000837.1

Schizophrenia refractory to first- and second-generation antipsychotics should be treated with clozapine (Clozaril).^20,44 In a meta-analysis comparing first- and second-generation antipsychotics with clozapine, higher rates in symptom reduction were shown with clozapine over a three-month period (NNT = 9).⁴⁴ Individuals receiving treatment with clozapine had a higher likelihood of experiencing sialorrhea (number needed to harm [NNH] = 4), seizures (NNH = 17), tachycardia (NNH = 17), and dizziness (NNH = 11).⁴⁴

In the United States, clozapine has an FDA boxed warning highlighting the risk of severe neutropenia (e.g., agranulocytosis), myocarditis, cardiomyopathy, seizures, and profound hypotension. Clozapine requires additional training and enrollment in the Risk Evaluation and Mitigation Strategy program (https://www.newclozapinerems.com/home#) [corrected].²⁰

Schizophrenia is not treatment resistant if patients are receiving subtherapeutic doses of antipsychotics due to lack of adherence to their treatment regimen. Long-acting injectables increase adherence to therapy.⁴⁵ In a meta-analysis comparing oral therapy with long-acting injectable therapy, patients taking long-acting injectables were found to have reduced hospitalizations in their lifetime (NNT = 6) and decreased rates of discontinuation from therapy (NNT = 10).⁴⁶

ADJUNCTIVE TREATMENTS

A systematic review and meta-analysis found that adjunctive electroconvulsive therapy in addition to clozapine for four to 12 weeks was superior to clozapine monotherapy in providing symptom improvement in patients with treatment-resistant schizophrenia (NNT = 3).⁴⁷ However, electroconvulsive therapy was associated with memory impairment (NNH = 4) and headache (NNH = 8).

In a systematic review that analyzed psychosocial interventions, including cognitive behavior therapy for psychosis, psychoeducation, supported employment services, assertive community care, and family interventions, treatment was associated with improved functional outcomes measured as the ability to function in social and occupational settings.²⁴ Relapse was reduced with family interventions, psychoeducation, illness self-management, and early interventions following a first episode of psychosis.²⁴ A systematic review and meta-analysis found that cognitive remediation implemented by a trained therapist in conjunction with a structured development of cognitive strategies and integration with rehabilitation was effective in improving cognition and functioning.⁴⁸ The American Psychiatric Association recommends that patients with a first episode of psychosis who receive a formal diagnosis of schizophrenia should be treated in a coordinated specialty care program.^20,24

Prognosis

The clinical course and prognosis of people with schizophrenia are marked with heterogeneity with variations in remission and exacerbations, making the disease course unpredictable. People with schizophrenia have mortality rates two to four times greater than the general population.⁴⁹ Factors contributing to increased mortality include concomitant psychiatric disorders, substance use disorders, and suicide.⁵⁰ However, most deaths are related to an increased rate of cardiovascular disease with concomitant renal disease, respiratory diseases, stroke, cancer, and thromboembolic events.⁵⁰ People with schizophrenia should be screened by a primary care physician for cardiovascular disease and receive at least annual metabolic screening and counseling with interventions to prevent weight gain and attempt to mitigate other factors that could contribute to their overall health, such as smoking. People with schizophrenia who smoke cigarettes should be offered cessation therapy to achieve abstinence.²³ A meta-analysis found that varenicline (Chantix) was superior to bupropion (Zyban) for tobacco cessation, but no significant difference was found between varenicline or bupropion and nicotine replacement therapy.⁵¹

A large population-based cohort study found a higher rate of all-cause mortality in patients not receiving clozapine than in those treated with clozapine.⁵² Another large cohort study found that maintenance therapy with antipsychotic medications reduces rates of suicide and overall mortality.⁵³

This article updates previous articles on this topic by Schultz, et al.,⁵⁴ and Holder and Wayhs.¹⁸

Data Sources: We were provided a search from Essential Evidence Plus using the search term schizophrenia. We searched the National Institute for Health and Care Excellence, U.S. Preventive Services Task Force, Cochrane database, OVID, Agency for Healthcare Research and Quality, and the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. A PubMed search was completed using the search terms schizophrenia, schizophrenia diagnosis, schizophrenia treatment, antipsychotics, schizophrenia prognosis, tardive dyskinesia, and schizophrenia mortality. Search dates: October 2021, December 2021, April 2022, and August 2022.

This manuscript represents the work of the authors. Opinions herein do not represent the U.S. Air Force, U.S. Department of Defense, or the Uniformed Services University of the Health Sciences.

Desai PR, Lawson KA, Barner JC, et al. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J Manag Care Pharm. 2013;19(6):468-477.

Gara MA, Vega WA, Arndt S, et al. Influence of patient race and ethnicity on clinical assessment in patients with affective disorders. Arch Gen Psychiatry. 2012;69(6):593-600.

Cohen CI, Marino L. Racial and ethnic differences in the prevalence of psychotic symptoms in the general population. Psychiatr Serv. 2013;64(11):1103-1109.

Schwartz RC, Blankenship DM. Racial disparities in psychotic disorder diagnosis: a review of empirical literature. World J Psychiatry. 2014;4(4):133-140.

Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013: 87–118.

Kishi T, Ikuta T, Matsui Y, et al. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med. 2019;49(5):772-779.

Viron M, Baggett T, Hill M, et al. Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. Am J Med. 2012;125(3):223-230.

Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379(3):270-280.

Mongan D, Ramesar M, Föcking M, et al. Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry. 2020;14(4):385-397.

McCutcheon RA, Marques TR, Howes OD. Schizophrenia–an overview. JAMA Psychiatry. 2020;77(2):201-210.

Zamanpoor M. Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatr Genet. 2020;30(1):1-9.

Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019;381(18):1753-1761.

Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002;159(7):1080-1092.

Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-1213.

Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-1269.

Nielsen SM, Toftdahl NG, Nordentoft M, et al. Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychol Med. 2017;47(9):1668-1677.

Petersen L, Jeppesen P, Thorup A, et al. Substance abuse and first-episode schizophrenia-spectrum disorders. The Danish OPUS trial. Early Interv Psychiatry. 2007;1(1):88-96.

Holder SD, Wayhs A. Schizophrenia. Am Fam Physician. 2014;90(11):775-782.

Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383-402.

Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872.

Leucht S, Bauer S, Siafis S, et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis. JAMA Psychiatry. 2021;78(11):1238-1248.

Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical anti-psychotics for schizophrenia. Cochrane Database Syst Rev. 2013(11):CD006625.

Kreyenbuhl J, Buchanan RW, Dickerson FB, et al.; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.

McDonagh MS, Dana T, Selph S, et al. Treatments for schizophrenia in adults: a systematic review. Comparative effectiveness review no. 198. AHRQ publication no. 17(18)-EHC031-EF. Agency for Health-care Research and Quality; October 2017. Accessed August 17, 2022. https://effectivehealthcare.ahrq.gov/topics/schizophrenia-adult/research-2017

Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis [published correction appears in Lancet. 2019; 394(10202): 918]. Lancet. 2019;394(10202):939-951.

Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-229.

Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199-210.

Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72(suppl 1):4-8.

Hartling L, Abou-Setta AM, Dursun S, et al. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157(7):498-511.

Goff DC, Falkai P, Fleischhacker WW, et al. The long-term effects of anti-psychotic medication on clinical course in schizophrenia [published correction appears in Am J Psychiatry. 2017; 174(8): 805]. Am J Psychiatry. 2017;174(9):840-849.

Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020(8):CD008016.

National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. February 12, 2014. Accessed August 17, 2022. http://www.nice.org.uk/Guidance/CG178

Toulany A, Stukel TA, Kurdyak P, et al. Association of primary care continuity with outcomes following transition to adult care for adolescents with severe mental illness. JAMA Netw Open. 2019;2(8):e198415.

Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.

Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019;59:151-154.

Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.

Artukoglu BB, Li F, Szejko N, et al. Pharmacologic treatment of tardive dyskinesia: a meta-analysis and systematic review. J Clin Psychiatry. 2020;81(4):19r12798.

Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-318.

Mazereel V, Detraux J, Vancampfort D, et al. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol (Lausanne). 2020;11:573479.

de Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.

Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-1403.

Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168-1178.

Kumari S, Malik M, Florival C, et al. An assessment of five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used symptoms rating scales in schizophrenia and comparison to newer scales (CAINS, BNSS). J Addict Res Ther. 2017;8(3):324.

Siskind D, McCartney L, Goldschlager R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385-392.

Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220-230.

Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603-619.

Wang G, Zheng W, Li XB, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;105:23-32.

Vita A, Barlati S, Ceraso A, et al. Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2021;78(8):848-858.

Cho J, Hayes RD, Jewell A, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand. 2019;139(3):237-247.

Lwin A, Symeon C, Jan F, et al. Morbidity and mortality in schizophrenia. Br J Hosp Med (Lond). 2011;72(11):628-630.

Siskind DJ, Wu BT, Wong TT, et al. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. Lancet Psychiatry. 2020;7(9):762-774.

Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017;174(10):990-998.

Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.

Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821-1829.